Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.
CDER director urges manufacturers to work with FDA to fix inspection issues before shutting down
As policymakers continue to chip away at fixes to ongoing drug shortages, the FDA’s drug center head is urging manufacturers to work with FDA on
September 19, 2023